In 2017, personal genetics company 23andMe announced that it had received FDA approval to provide people with their apolipoprotein E (APOE) genotype and nine other genes linked with health risks. The APOE gene is associated with late-onset Alzheimer’s disease (AD), the leading cause of dementia.In this chapter, I argue that APOE testing is of limited clinical significance given the present lack of disease-modifying therapies for AD and the fact that preventive measures are the same regardless of an individual’s APOE status.Nevertheless, an APOE result can have great personal and legal significance to individuals–for instance, influencing decision-making around insurance, employment, end-of-life care.One way to reconcile the obvious tension between paternalism and the individual’s right to know their genetic risk for late-onset AD is to provide genetic information in the context of robust information about the personal and legal ramifications of the result.This, I argue, is an area were 23andMe and other DTC genetic testing companies fall short.